Menu Search
Equities

Boule Diagnostics AB

8BD:STU

Boule Diagnostics AB

Actions
  • Price (EUR)0.55
  • Today's Change-0.042 / -7.09%
  • Shares traded0.00
  • 1 Year change-28.39%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Boule Diagnostics AB grew revenues 4.24% from 548.09m to 571.33m while net income improved 96.24% from 12.73m to 24.98m.
Gross margin45.14%
Net profit margin-37.74%
Operating margin-44.67%
Return on assets-32.14%
Return on equity-57.47%
Return on investment-48.62%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Boule Diagnostics AB fell by 59.62m. However, the company earned 51.38m from its operations for a Cash Flow Margin of 8.99%. In addition the company used 82.71m on investing activities and also paid 25.51m in financing cash flows.
Cash flow per share-4.69
Price/Cash flow per share--
Book value per share6.56
Tangible book value per share2.28
More ▼

Balance sheet in SEKView more

Boule Diagnostics AB has a Debt to Total Capital ratio of 41.16%, a higher figure than the previous year's 12.77%.
Current ratio1.04
Quick ratio0.7686
Total debt/total equity0.6995
Total debt/total capital0.4116
More ▼

Growth rates in SEK

SmartText is unavailable
Div yield(5 year avg)0.51%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)-15.62
EPS (TTM) vs
TTM 1 year ago		-1,144.76
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.